High risk for latent tuberculosis infection among medical residents and nursing students in India.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2019
Historique:
received: 28 11 2018
accepted: 17 06 2019
entrez: 9 7 2019
pubmed: 10 7 2019
medline: 3 3 2020
Statut: epublish

Résumé

Defining occupational latent tuberculosis infection (LTBI) risk among healthcare workers is needed to support implementation of prevention guidelines. Prospective cohort study of 200 medical residents and nursing students in India was conducted May 2016-December 2017. Tuberculin skin test (TST) and QuantiFERON TB Gold Test-in-tube (QFT-GIT) were performed at study entry and 12 months. Primary outcome was incident LTBI (≥10mm TST induration and/or ≥0.35IU/mL QFT-GIT) at 12 months; secondary outcomes included baseline LTBI prevalence and risk factors for incident and prevalent LTBI using Poisson regression. Among 200, [90 nursing students and 110 medical residents], LTBI prevalence was 30% (95% CI, 24-37); LTBI incidence was 26.8 (95% CI, 18.6-37.2) cases per 100 person-years and differed by testing method (28.7 [95% CI, 20.6-38.9] vs 17.4 [95% CI, 11.5-25.4] cases per 100 person-years using TST and QFT-GIT, respectively). Medical residents had two-fold greater risk of incident LTBI than nursing students (Relative Risk, 2.16; 95% CI, 1.05-4.42). During study period 6 (3%) HCWs were diagnosed with active TB disease. Overall, median number of self-reported TB exposures was 5 (Interquartile Range, 1-15). Of 60 participants with prevalent and incident LTBI who were offered free isoniazid preventive therapy (IPT), only 2 participants initiated and completed IPT. High risk for LTBI was noted among medical residents compared to nursing students. Self-reported TB exposure is underreported, and uptake of LTBI prevention therapy remains low. New approaches are needed to identify HCWs at highest risk for LTBI.

Identifiants

pubmed: 31283794
doi: 10.1371/journal.pone.0219131
pii: PONE-D-18-34087
pmc: PMC6613683
doi:

Substances chimiques

Antitubercular Agents 0
Isoniazid V83O1VOZ8L

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0219131

Subventions

Organisme : FIC NIH HHS
ID : D43 TW009574
Pays : United States
Organisme : NIAID NIH HHS
ID : U01 AI069465
Pays : United States

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Emerg Infect Dis. 2016 Mar;22(3):541-3
pubmed: 26889712
Clin Infect Dis. 2016 May 15;62 Suppl 3:S262-7
pubmed: 27118856
Am J Respir Crit Care Med. 2000 Apr;161(4 Pt 2):S221-47
pubmed: 10764341
PLoS One. 2010 Apr 29;5(4):e10408
pubmed: 20454447
Braz J Infect Dis. 2013 May-Jun;17(3):383-4
pubmed: 23607917
Clin Infect Dis. 2016 May 15;62 Suppl 3:S255-61
pubmed: 27118855
PLoS One. 2013;8(3):e58202
pubmed: 23536789
PLoS One. 2009 Aug 27;4(8):e6798
pubmed: 19710920
Emerg Infect Dis. 2011 Mar;17(3):488-94
pubmed: 21392441
Clin Infect Dis. 2016 May 15;62 Suppl 3:S238-43
pubmed: 27118853
JAMA. 2005 Jun 8;293(22):2746-55
pubmed: 15941804
Epidemiol Infect. 2015 Sep;143(12):2639-47
pubmed: 25544572
Open Forum Infect Dis. 2017 Aug 29;4(3):ofx137
pubmed: 28875155
Int J Tuberc Lung Dis. 2005 Aug;9(8):841-7
pubmed: 16104628
Int J Tuberc Lung Dis. 2003 Jun;7(6):556-62
pubmed: 12797698
J Clin Epidemiol. 2013 Jan;66(1):67-74
pubmed: 22521578
Int J Tuberc Lung Dis. 2003 Apr;7(4):306-11
pubmed: 12729334
Tuberc Res Treat. 2017;2017:7514817
pubmed: 29359043
Am J Respir Crit Care Med. 2001 Sep 15;164(6):962-4
pubmed: 11587979
PLoS Med. 2006 Dec;3(12):e494
pubmed: 17194191
Bull World Health Organ. 2002;80(7):526-31
pubmed: 12163915
BMC Infect Dis. 2011 Jan 18;11:19
pubmed: 21244645

Auteurs

Aarti Kinikar (A)

Department of Pediatrics, BJGMC-JHU Clinical Trial Unit, Byramjee-Jeejeebhoy Government Medical College, Pune, Maharashtra, India.

Ajay Chandanwale (A)

Department of Orthopedics, BJGMC-JHU Clinical Trial Unit, Byramjee-Jeejeebhoy Government Medical College, Pune, Maharashtra, India.

Dileep Kadam (D)

Department of Medicine, Smt. Kashibai Navale Medical College and General Hospital, Pune, Maharashtra, India.

Samir Joshi (S)

Department of ENT, BJGMC-JHU Clinical Trial Unit, Byramjee-Jeejeebhoy Government Medical College, Pune, Maharashtra, India.

Anita Basavaraj (A)

Department of Medicine, Government Medical College, Miraj, Maharashtra, India.

Geeta Pardeshi (G)

Department of Community Medicine, Vardhman Mahavir Medical College and Safdarjung Hospital, New Delhi, India.

Sunita Girish (S)

Department of Biochemistry, BJGMC-JHU Clinical Trial Unit, Byramjee-Jeejeebhoy Government Medical College, Pune, Maharashtra, India.

Sangeeta Shelke (S)

Department of Community Medicine, BJGMC-JHU Clinical Trial Unit, Byramjee-Jeejeebhoy Government Medical College, Pune, Maharashtra, India.

Andrea DeLuca (A)

Department of Environmental Health and Engineering, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, United States of America.

Gauri Dhumal (G)

BJGMC-JHU Clinical Trial Unit, Byramjee-Jeejeebhoy Government Medical College, Pune, Maharashtra, India.

Jonathan Golub (J)

Department of Medicine, Epidemiology and International Health, Johns Hopkins University School of Medicine and the Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States of America.

Nilima Lokhande (N)

BJGMC-JHU Clinical Trial Unit, Byramjee-Jeejeebhoy Government Medical College, Pune, Maharashtra, India.

Nikhil Gupte (N)

BJGMC-JHU Clinical Trial Unit, Byramjee-Jeejeebhoy Government Medical College, Pune, Maharashtra, India.
Department of Medicine, Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America.

Amita Gupta (A)

Department of Medicine, Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America.

Robert Bollinger (R)

Department of Medicine, Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America.

Vidya Mave (V)

BJGMC-JHU Clinical Trial Unit, Byramjee-Jeejeebhoy Government Medical College, Pune, Maharashtra, India.
Department of Medicine, Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH